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ment recommendation by performing the Pearson’s Chi-squared test, Kolmogorov-
Smirnov test, and Wilcoxon rank sum test. Results: In total, 53 pharmacoeconomic 
evaluations were included in this study. Of these, 16 concerned orphan drugs, while 
37 evaluated high cost- drugs. Of the 53 pharmaceutical compounds evaluated in 
this study, 39 (73.6%) received a positive reimbursement advice, 11 (20.8%) received 
a negative reimbursement advice, and 3 drugs were not assessed for reimburse-
ment through either the outpatient reimbursement system nor the intramural 
high cost reimbursement system (5.7%). In total, 277 deviations from the phar-
macoeconomic guidelines were observed, but no single item was found to have a 
statistically significant effect on the reimbursement recommendation. In contrast 
to drug safety and cost-effectiveness outcomes, both drug efficacy and therapeutic 
value showed to have statistically significant impact on the reimbursement deci-
sion. ConClusions: In The Netherlands, drug efficacy and therapeutic value can 
be considered as essential criteria in the reimbursement decision of orphan and 
expensive pharmaceuticals, resulting in a reimbursement system being centered 
on clinical value. Even though cost-effectiveness does not have a significant impact 
on the decision, compliance in the reimbursement dossiers by manufacturers to 
the Dutch Guidelines for Pharmacoeconomic research can be further improved.
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objeCtives: The diagnosis-related group (DRG) based reimbursement system has 
been voluntarily applied to inpatients with seven diseases in the Korean national 
health insurance since 2002, and was mandatory for all health-care institutions 
from July 1, 2013. The main purpose of this study was to evaluate the perfor-
mance of DRG-based reimbursement in health care expenditure and to propose 
alternative policies. Methods: A non-equivalent control group pretest-posttest 
design with a difference-in-difference approach was adopted to compare changes 
in medical service utilization and physician’s behavior between DRG-based 
reimbursement(experimental group) and fee-for-service reimbursement(control 
group). Seven diseases to which DRG-based reimbursement was applied included 
tonsillectomy, cataract surgery, appendectomy, herniotomy, hemorrhoidectomy, 
hysterectomy, and Caesarean section. The panel data were produced from year 
2004~2011 medical claims database of the National Health Insurance, which covered 
a total of 1,119,028 cases per year. Results: From 2004 to 2011, surgical operations 
in institution reimbursed by DRG have been significantly increased more than those 
in institutions reimbursed by fee-for-service. The results showed that the DRG-based 
payment has reduced the length of stay in seven diseases, while it has changed phy-
sician’s behavior to charge DRG-code upward and shift medical tests and expensive 
antibiotics from inpatients to outpatients because DRG was applied to inpatient 
only. The DRG-based payment in seven diseases has consistently increased medi-
cal expenditure as well as medication expenses more than fee-for-service, partly 
due to no global budget in the Korean national health insurance. ConClusions: 
Challenges and future issues to expand the DRG-based reimbursement system to 
all diseases for inpatients should be considered such as monitoring service quality, 
strategic plans to control physicians’ behavior, limiting the number of DRG clas-
sifications, and the introduction of global budgeting.
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objeCtives: Beginning in 2014, the Affordable Care Act requires new health 
plans to cover essential health benefits (EHB), including pharmaceutical products, 
according to the state level benchmark plans. The objectives of this analysis were 
to understand state level variations in design of plans, access to drugs and likely 
impact on patient choice and health outcomes. Methods: Benchmark plans for 
the top five states (i.e., FL, IL, NY, TX and CA), covering ~116 million lives, were 
obtained from the CMS. For each plan, the categories, classes and number of cov-
ered drugs was collected and pooled into one database. Analysis was conducted at 
the entire population level, state-level and for top classes of drugs. The comments 
from patient groups were reviewed to understand the impact of EHB on patient 
choice and health outcomes. Results: Benchmark plans for the top five states 
provide coverage of 4215 drugs belonging to 158 classes as defined by USP. While 
four states (FL, IL, NY and TX) had a similar number of covered drugs (median of 
892 drugs), CA had a significantly lower number of covered drugs, amounting to 
28% less than the other four states. On average, 10% of the drugs were in the class 
called “No USP Class”, highlighting the limitation of CMS designated USP clas-
sification system for the new plans. In CA, FL, IL, NY and TX there were 18, 7, 8, 11 
and 8 classes, respectively, for which only 1 was covered. In CA, top 8 classes were 
identified for which patients had a 75% lower choice than other states, and these 
included indications such as Anti-Diabetics and Pain medications. ConClusions: 
Review of new benchmark plans shows some states can have a significantly lower 
patient choice of therapies. There is a need for new policy measures to ensure that 
all patients have equal access to new treatments.
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objeCtives: International Reference Pricing (IRP) is a key cost-containment tool 
for health care payers across the world. IRP may apply either fixed or flexible 
determine any trends and drivers of local decision-making. Results: As expected, 
there was variation across CCGs in funding decisions. However, there was only a 
limited correlation between funding decisions and CCG priorities or performance. 
It became evident that there were no strong discernible trends or drivers for local 
funding decisions on these products. ConClusions: Unlike the national level 
assessments undertaken by NICE, the drivers of local formulary decisions on new 
pharmacotherapies are difficult to establish and vary across CCG, making it dif-
ficult for pharmaceutical companies to obtain access for their medicines using a 
“one size fits all” approach. Thus, pharmaceutical companies need to engage more 
closely with CCGs to better understand their needs (including beyond-the-pill) and 
demonstrate the ‘localised’ value of pharmacotherapies.
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objeCtives: Since the introduction of the AMNOG in January 2011, an early benefit 
assessment by the German G-BA is required for all new drugs in Germany. Objective 
of our study was to identify any predictors of G-BA decisions. Methods: All G-BA 
decisions up to 04/2015 were analyzed; basic characteristics of each drug as well as 
of each decision were documented. A multivariate ordinal regression analysis, using 
given additional benefit classification (ranging from 1 for major additional benefit 
to 5 for no additional benefit) as dependent variable, was conducted. Results: 130 
completed G-BA assessment procedures were evaluated. Within these, G-BA deci-
sions were as follows: 16.9% of the drugs received considerable additional benefit 
(for at least one patient subgroup), 23.1% received a minor additional benefit, 10.0% 
received a non-quantifiable additional benefit, and 50.0% received no additional 
benefit. Due to the specifics of German value assessment, orphan drugs auto-
matically receive an additional benefit, but 39.1% of the assessed drugs received a 
non-quantifiable additional benefit (lowest possible assessment). Our multivariate 
regression analysis showed that the strongest predictors for an above-average ben-
efit ranking were proven advantages in mortality (p< 0.001) or morbidity (p= 0.001). 
Additionally, products for use in malignant (p= 0.013) or infectious diseases (p< 0.001) 
as well as orphan treatments (p= 0.027) were more likely to reach a better benefit 
rating. Furthermore, any evidence of a favorable safety profile of a treatment is 
associated with a better ranking (p= 0.10). ConClusions: Key factors for positive 
G-BA decisions seem to be a proven superiority in mortality or morbidity against 
the standard treatment as defined by the German G-BA. However, this is difficult 
to prove in specific chronic disease areas, especially if surrogate outcomes are not 
widely accepted. This may explain why, for example, 80% of the assessed diabetes 
drugs did not receive any additional benefit in Germany.
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objeCtives: In Germany, the reimbursement and pricing of innovative in-patient 
drugs and devices is managed through the NUB application process. These applica-
tions are submitted by the hospital stakeholder and are approved or rejected by the 
Institute for the Hospital Remuneration System (InEK ). The objective of this research 
was to assess the NUB trends in Germany in 2012-2014. Methods: We developed 
a database of NUB approvals and rejections based on the Institute for the Hospital 
Remuneration System’s (InEK )’s reports. All information was extracted into Excel 
format. The following data was extracted: product name, indication, year of submis-
sion, number of NUB applications submitted, status score, type of evidence available 
and lack of evidence for NUB rejection. Additionally, the number of re-applications 
and re-rejections were also analyzed. Results: In 2013 and 2014, a total of 21264 
and 25634 NUB applications were submitted for 612 and 613 medical products, 
respectively. Of these applications in 2013 and 2014, 10% and 16% were approved 
for NUB (as Status 1) and 82% and 75% were rejected (as Status 2), respectively. In 
2014, the median number of hospital applications for NUBs with Status 1 and Status 
2 were 37 and 3, demonstrating the importance of hospital participation for seek-
ing NUB approval. Among approved NUBs, 37% of the applications were for drugs 
and 63% were for devices. Interestingly, the median NUB hospital applications for 
approved drugs was 192, while for devices, the median was 9 applications. In 2014, 
447 NUB applications for products were re-submitted, of which 5 were approved and 
the remaining were re-rejected. The evidence requirements analysis suggests the 
need for hospital focused economic data. ConClusions: The NUB process plays 
a critical role in market access for in-patient drugs and devices. For approval, two 
key components are: hospital focused economic evidence and provider stakeholder 
involvement.
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objeCtives: The aim of this study is to (i) review the methodological quality of 
pharmacoeconomic evaluations of orphan and expensive drugs that applied for 
reimbursement in The Netherlands, and (ii) explore essential criteria in the reim-
bursement recommendations made by The Dutch National Healthcare Institute 
(ZINL). Methods: Data were extracted from pharmacoeconomic reports published 
by ZINL between 1 January 2006 and 31 December 2013 using a data extraction 
form. Compliance to pharmacoeconomic guidelines was determined by evaluat-
ing deviations in the pharmacoeconomic reports from the list of provided items in 
the guidelines. Multiple variables (i.e. drug safety, efficacy, therapeutic value, and 
cost-effectiveness) were investigated regarding their influence on the reimburse-
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It is often assumed that the assessment by the SMC influences subsequent local 
recommendations on the funding and use of medicines in England. This research 
tests that hypothesis. Methods: Research was based on 86 medicines assessed 
by the SMC in 2012 and 2013, of which 56 were not reviewed by NICE. A sample of 
five local assessment groups in England was identified. From these we found a total 
of 53 recommendations relating to medicines not reviewed by NICE, of which 27 
were published subsequent to the SMC assessment. Results: Only around half 
(51%) of local assessments in England were published subsequent to SMC assess-
ments, so could potentially have been influenced. Of these recommendations 
two-thirds (18) were consistent with the SMC verdict, and one third (9) differed. 
Detailed analysis revealed additional factors. Several of the medicines in the sam-
ple were recommended by NICE on the basis of evidence summaries or in clinical 
guidelines. This advice, although not mandatory, appears from our sample to have 
been followed. Also some medicines not recommended by SMC were subject to 
specialised commissioning, the responsibility of NHS England rather than local 
commissioners. ConClusions: There is some consistency between assessments 
of new medicines in Scotland and England (as might be expected given that the 
evidence and decision criteria are broadly similar) but there are also significant dif-
ferences. It appears English advisory bodies make their decisions independently of 
SMC recommendations, and often earlier. Other differences, such as NICE evidence 
summaries and Specialised Commissioning in England, further reduce the influ-
ence of Scottish decisions.
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objeCtives: The framework specifications on pharmaceuticals (Rahmenvorgaben 
Arzneimittel) by the National Association of Statutory Health Insurance-Accredited 
Physicians (KBV) and the Statutory Health Insurance Scheme (GKV-Spitzenverband) 
are annually redefined. These specifications (Rahmenvorgaben) are binding for 
the 17 subnational drug agreements (Arzneimittelvereinbarungen) and target 
agreements (Zielvereinbarungen). They include quotas for lead compounds and 
prescription quotas. Individual subnational districts (KV Gebiete) set local drug 
specifications and quotas. These guide the prescription behavior. The objective of 
the analysis is to identify differences between the subnational regions regarding 
target agreements and resulting impacts. The analysis focuses also on the shift from 
innovative biologics to biosimilar products. Methods: The 17 subnational drug 
target agreements (Zielvereinbarungen) are analyzed regarding their differences/ 
specialities and their regulatory effect on the prescription of pharmaceutical classes 
e.g. anti-diabetic, anti-hypertensives, and the biosimilar proportion. Additionally 
the rapid prescription information of the SHI (GKV-Arzneimittel-Schnellinformation 
= GAmSi-data) and local regulation instruments are reviewed. Results: The 17 tar-
get agreements (Zielvereinbarungen) for the 15 defined classes of pharmaceuticals 
result in different quota fulfillment. An example is erythropoetin with a quantita-
tive quota range from 20% to 63%. The qualitative regulatory actions regarding the 
switch of biologics (Erythropoetin, Somatropin, Filgrastim, TNF alpha-blocker) to 
biosimilars vary from no regulation to recommendation or even priority prescrip-
tion. The additional defined subnational target agreements (Zielvereinbarungen) 
include targets on diabetes test strips, biosimilar quotas, individual substances or 
product-classes and can be individually adapted for the different physician spe-
cialties. ConClusions: In addition to the federal regulation system the German 
pharmaceutical market is fragmented in 17 subnational areas leading to different 
treatment behavior depending on the relevant subnational target agreements and 
the defined quotas. This analysis shows the wide variety of the subnational target 
agreements for different drug classes. They are not uniform and on a qualitative 
basis they even can exceed the determined federal targets.
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objeCtives: Since the introduction of AMNOG more than 100 IQWiG recommenda-
tions and G-BA decisions on the early benefit assessment have been published. In 
various assessments, the IQWiG recommendation and the related G-BA decision differ 
in terms of argumentation and result. In this study, these differences were systemati-
cally analyzed in order to draw conclusions for further proceedings. Methods: Data 
of all published IQWiG recommendations and G-BA decisions were standardized and 
transferred into the Prismaccess database. In a systematic analysis, major differ-
ences between the recommendations and decisions were quantitatively assessed. 
All documents of the identified decisions where differences were observed were 
then compared qualitatively. Results: In several aspects, major differences were 
found between IQWiG recommendations and G-BA decisions in approximately 25% 
of all cases. On the subgroup level, it was observed in at least n= 10 cases that the 
G-BA tends to use a broader definition of subgroups in its decisions than used in the 
IQWiG dossiers, (e.g. Telaprevir). In terms of the extent of the additional benefit, 17 
differences between IQWiG and G-BA decisions were registered, while mostly G-BA 
tend to evaluate better than IQWiG. In the probability of the additional benefit also 
some differences were observed. This can be explained by the opportunity to provide 
additional/new evidence during the oral hearing, which may influence the decision 
positively. Some proceedings were identified that took another way, as intended by 
the legislature: for example with Cobicistat, an incomplete paperwork was handed 
in, to achieve at least the price of the ACT. Still accepted by the G-BA, it is obvious 
that this should not be the normal case. ConClusions: In an early stage, G-BA 
consultations might be helpful clarifying subgroups-requirements. In the process, 
the oral hearing was identified as important instrument to supplement the required 
data and to correct uncertain issues from the dossier.
rules to calculate the price of branded drugs. Typically there is no negotiation 
between manufacturers and the IPR body. In the context of the German AMNOG 
price negotiations and the role of Germany as a key reference country, there is 
dearth of evidence on the international impact of the AMNOG law. Our objective 
was to evaluate the potential impact. Methods: An IRP tool (Orange) was used 
to simulate scenarios of price agreements for a new branded drug between the 
German Head Association of the Statutory Health Insurance Companies and the 
manufacturer. The impact of the price agreement on other countries was evalu-
ated based on the existing IRP rules as defined in the Orange tool. All prices were 
initially set at 100 euro to limit the impact to Germany only. Results: A 50% 
price drop in Germany, for example, would lead to a range of reductions across 
the world. The largest impact in Europe would be in France, Romania, Russia, 
Slovenia and Luxembourg (50% decrease) followed by Norway, Greece (17%) and 
the Netherlands (13%). Switzerland, Ireland, Denmark and Austria would be only 
marginally impacted. In contrast, with a price increase in Germany of 25% a limited 
impact in other countries was observed. Such an increase would lead to 6% price 
rise in the Netherlands, 4% in Switzerland, 3% in Ireland and Denmark, and a 1% 
increase in Austria. ConClusions: Price negotiations in Germany could poten-
tially impact the price of new branded therapies in numerous other countries. 
Ongoing downward pressure on pharmaceutical prices could ultimately have a 
negative impact on innovation and drug development in Europe.
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objeCtives: Both ultra orphan and cancer drugs are premium priced therapies 
with high annual per patient costs. The local legislation and reimbursement 
mechanisms have had significant impact on pricing trends for these therapies. 
The objectives of this analysis were to compare the price differential for ultra 
orphan and cancer drugs in the US and the UK, and understand the impact of 
local reimbursement mechanisms. Methods: A set of 22 drugs (10 ultra orphan 
and 12 cancer drugs) was selected based on their availability in the US and the UK. 
The 2014 AWP, WAC and net prices were obtained for all 22 drugs. All UK prices 
were converted to USD. Primary discussions with ex-payer and policy experts 
were conducted to understand the basis and implication of the price differen-
tials. Results: For ten selected ultra orphan drugs, the median WAC price pre-
mium for the US compared to the UK net price was 10%. For 12 selected cancer 
drugs the median WAC price premium for the US compared to the UK net price 
was 106% (based on AWP the premiums were 29% and 149%, respectively). Eight 
out of 10 ultra orphan and 12 out of 12 cancer drugs were higher priced in the US 
compared to the UK. Primary discussions with experts suggest the role of legisla-
tion for coverage of cancer drugs in the US and special coverage of rare disease 
products in the UK and reimbursement mechanisms (use of cost effectiveness 
driven HTAs in the UK and the use of co-pay in the US) as primary drivers of high 
price differential for cancer drugs versus ultra orphan therapies. ConClusions: 
The local reimbursement mechanisms are major drivers of price differential for 
ultra orphan and cancer drugs in the US and the UK.
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objeCtives: Pharmaceutical industry continues to grow and drug prices are a bur-
den for countries. Reference price system is assumed that such a practice concern-
ing medicines will lead to a decrease in medicine expenditures as medicine prices 
decrease. The objectives of this analysis to determine the distribution of discount 
of original medicines which has no generics from the reimbursement agency per-
spective in Turkey. Methods: In the analysis,“Detailed Price List” data published 
on the website of the Ministry of Health’s Turkish Medicines and Medical Devices 
Agency(TMMDA) and “Annex 4-A Funded Medicines List” data published by Social 
Security Institution(SSI) were used. The lists were merged using the Excel software 
and generic medicine including genericized original medicines with different pric-
ing and payment conditions compared to original medicines with no generics and 
other specific medicines such as blood products,enteral nutrition products, etc. and 
specific conditions such as medicines with no reimbursement were excluded. The 
analysis was made with a total of 568 original medicines with no generic. Ex-factory 
prices were used in the analysis. The reference prices of all original medicines 
(100%)are calculated by multiplying their actual reference price values with the 
periodic Euro value in the price list used in Turkey. Results: A comparison between 
ex-factory prices in TL and actual reference prices in TL revealed that 42.6% of the 
medicines had the same price,while 57.4% had a different price.The distribution of 
discount rates applied by SSI for 370 original medicines with a 41% discount rate 
and 99 original medicines with a 32.5% discount rate were found. ConClusions: 
In this analysis the mandatory discount rate for original drugs of 41% discount 
is mostly implemented by SSI. In rare cases, higher or lower discount rate can be 
applied. This is compatible with the implementation of the original drug reimburse-
ment policy rules. However, further analysis should be done to obtaining more 
detailed information.
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objeCtives: The Scottish Medicines Consortium (SMC), unlike the National 
Institute for Health and Care Excellence in England, assesses all new medicines. 
